Zentalis Pharmaceuticals
ZNTL
66 hedge funds and large institutions have $1.05B invested in Zentalis Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 36 increasing their positions, 10 reducing their positions, and 3 closing their positions.
260% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 10
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
8% more funds holding
Funds holding: 61 → 66 (+5)
5.34% more ownership
Funds ownership: 74.86% → 80.2% (+5.3%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
18% less capital invested
Capital invested by funds: $1.28B → $1.05B (-$235M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$27.3M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$27M |
| 3 |
Primecap Management
Pasadena,
California
|
+$25.3M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$19.2M |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$14.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.86M |
| 2 |
ZP
Zimmer Partners
New York
|
-$2.64M |
| 3 |
Jane Street
New York
|
-$624K |
| 4 |
D.E. Shaw & Co
New York
|
-$593K |
| 5 |
MIM
MetLife Investment Management
Whippany,
New Jersey
|
-$178K |
ZNTL Hedge Fund Activity: Q3 2020 in Review
66 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Zentalis Pharmaceuticals (ZNTL) for Q3 2020, worth a combined $1.05B — down 18% from $1.28B a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new ZNTL positions and 3 closed out — a net gain of 5 holders — while 36 added to existing stakes and 10 trimmed.
The largest buyer was Federated Hermes, opening a new position worth an estimated $27.3M. The largest seller was T. Rowe Price Associates, cutting an estimated $2.86M.
- 66 institutional investors held Zentalis Pharmaceuticals (ZNTL) as of Q3 2020, up from 61 in Q2 2020.
- Funds reported $1.05B of Zentalis Pharmaceuticals stock for Q3 2020, down 18% quarter-over-quarter.
- 8 funds opened new Zentalis Pharmaceuticals positions in Q3 2020 and 3 closed out, a net change of +5 holders.
- The largest Zentalis Pharmaceuticals buyer in Q3 2020 was Federated Hermes, an estimated $27.3M added.
- The largest Zentalis Pharmaceuticals seller in Q3 2020 was T. Rowe Price Associates, an estimated $2.86M sold.
Based on aggregated 13F filings for Q3 2020.